Skip to main content
. 2021 Dec 10;9(12):e003645. doi: 10.1136/jitc-2021-003645

Table 2.

Treatment-emergent adverse events occurring in ≥10% of patients overall

Event, n (%) patients Enadenotucirev IP monotherapy (n=10) Enadenotucirev IP plus paclitaxel (n=8) Enadenotucirev IV plus paclitaxel (n=20) Overall (N=38)
Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3
Gastrointestinal disorders 10 (100) 4 (40) 8 (100) 2 (25) 12 (60) 2 (10) 30 (79) 8 (21)
 Diarrhea 7 (70) 3 (30) 4 (50) 0 5 (25) 0 16 (42) 3 (8)
 Nausea 7 (70) 0 2 (25) 0 7 (35) 1 (5) 16 (42) 1 (3)
 Abdominal pain 5 (50) 0 4 (50) 1 (13) 3 (15) 0 12 (32) 1 (3)
 Vomiting 5 (50) 1 (10) 2 (25) 0 3 (15) 1 (5) 10 (26) 2 (5)
 Constipation 0 0 2 (25) 0 4 (20) 0 6 (16) 0
 Ascites 1 (10) 0 2 (25) 1 (13) 1 (5) 0 4 (11) 1 (3)
General disorders and administration site conditions 8 (80) 0 6 (75) 0 13 (65) 1 (5) 27 (71) 1 (3)
 Fever 3 (30) 0 4 (50) 0 4 (20) 0 11 (29) 0
 Fatigue 2 (20) 0 2 (25) 0 4 (20) 0 8 (21) 0
 Asthenia 1 (10) 0 0 0 6 (30) 0 7 (18) 0
 Chills 2 (20) 0 2 (25) 0 3 (15) 0 7 (18) 0
 Edema peripheral 2 (20) 0 3 (38) 0 1 (5) 0 6 (16) 0
 Influenza-like illness 2 (20) 0 0 0 2 (10) 0 4 (11) 0
Blood/lymphatic system disorders 6 (60) 0 5 (63) 5 (63) 13 (65) 6 (30) 24 (63) 11 (29)
 Anemia 6 (60) 0 3 (38) 1 (13) 10 (50) 2 (10) 19 (50) 3 (8)
 Neutropenia/neutrophil count decreased 0 0 4 (50) 3 (38) 10 (50) 5 (25) 12 (32) 8 (21)
Infections and infestations 5 (50) 1 (10) 5 (63) 2 (25) 10 (50) 1 (5) 20 (53) 4 (11)
 Urinary tract infection 3 (30) 1 (10) 0 0 2 (10) 0 5 (13) 1 (10)
Nervous system disorders 6 (60) 1 (14) 3 (38) 0 6 (30) 0 15 (39) 1 (3)
 Lethargy 4 (40) 1 (14) 2 (25) 0 1 (5) 0 7 (18) 1 (3)
 Headache 3 (30) 0 1 (13) 0 1 (5) 0 5 (13) 0
Respiratory, thoracic and mediastinal disorders 3 (30) 0 3 (38) 2 (25) 5 (25) 0 11 (29) 2 (5)
 Dyspnea 3 (30) 0 1 (13) 0 2 (10) 0 6 (16) 0
 Cough 0 0 2 (25) 0 2 (10) 0 4 (11) 0
Metabolism and nutrition disorders 5 (50) 0 2 (25) 0 3 (15) 0 10 (26) 0
 Hypomagnesemia 1 (10) 0 1 (13) 0 2 (10) 0 4 (11) 0
Skin and subcutaneous tissue disorders 1 (10) 0 3 (38) 0 5 (25) 0 9 (24) 0
 Alopecia 0 0 2 (25) 0 4 (20) 0 6 (16) 0

IP, intraperitoneal; IV, intravenous.